Skip to main content
SpringerLink
Log in

Topiramate versus Carbamazepine for the Treatment of Classical Trigeminal Neuralgia

A Meta-Analysis

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background: Carbamazepine is currently the drug of first choice in the treatment of trigeminal neuralgia. However, it is reported as efficacious in only 70–80% of patients, and can be associated with adverse effects such as drowsiness, confusion, nausea, ataxia, nystagmus and hypersensitivity, which may necessitate discontinuation of medication. Therefore, alternative drugs such as oxcarbazepine, baclofen and topiramate are also used to treat the disease.

Objectives: The aim of this study was to compare the effectiveness and safety of topiramate with carbamazepine in the treatment of classical trigeminal neuralgia.

Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) [Issue 3 of 12, March 2011], MEDLINE, EMBASE, the Chinese Biomedical Database (CBM), the Chinese National Knowledge Infrastructure (CNKI) and the Chinese Science and Technique Journals Database (VIP) for the period January 1998 to March 2011, and we also manually searched all relevant journals. We included all confirmed randomized controlled trials treating trigeminal neuralgia with topiramate and carbamazepine. We evaluated the risk of bias of the included trials according to the Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1. The Cochrane Collaboration’s software RevMan 5.1 was used for the meta-analysis.

Results: A total of six randomized controlled trials with poor methodological quality were included. All trials were conducted in China. Altogether, they included 354 patients with trigeminal neuralgia. The results of the meta-analysis showed that topiramate was more effective than carbamazepine after a treatment duration of 2 months (relative risk [RR] = 1.20, 95% CI 1.04, 1.39, p = 0.01). However, no difference was found in the effectiveness rate after a treatment duration of 1 month (RR = 1.00, 95% CI 0.87, 1.14, p = 0.94), in the remission rate after a treatment duration of 1 month (RR = 1.06, 95% CI 0.83, 1.36, p = 0.63), in the remission rate after a treatment duration of 2 months (RR = 1.31, 95% CI 0.96, 1.80, p = 0.09) or in adverse events when comparing topiramate with carbamazepine.

Conclusions: Present trials comparing topiramate with carbamazepine are all poor in methodological quality. A meta-analysis of these studies showed that the overall effectiveness and tolerability of topiramate did not seem to differ from carbamazepine in the treatment of classical trigeminal neuralgia. However, the meta-analysis yielded a favourable effect of topiramate compared with carbamazepine after a treatment duration of 2 months. Results were limited due to the poor methodological quality and the geographic localization of the randomized controlled trials identified. Therefore, large, international, well conducted, randomized controlled trials are needed to further assess the relative efficacy and tolerability of topiramate and carbamazepine in this indication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Table III
Fig. 4

Similar content being viewed by others

References

  1. Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Seattle (WA): IASP Press, 1994: 59–71

    Google Scholar 

  2. Katusic S, Williams DB, Beard CM, et al. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945–1984. Neuroepidemiology 1991; 10: 276–81

    Article  PubMed  CAS  Google Scholar 

  3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24 Suppl. 1: 9–160

    Google Scholar 

  4. Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 2008; 15: 1013–28

    Article  PubMed  CAS  Google Scholar 

  5. Zakrzewska JM, McMillan R. Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J 2011; 87: 410–6

    Article  PubMed  Google Scholar 

  6. Zakrzewska JM. Assessment and treatment of trigeminal neuralgia. Br J Hosp Med 2010; 71(9): 490–4

    Google Scholar 

  7. Rockcliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1996; 15: 129–36

    Article  Google Scholar 

  8. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13(11): 1153–69

    Article  PubMed  CAS  Google Scholar 

  9. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71(15): 1183–90

    Article  PubMed  CAS  Google Scholar 

  10. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18(1): 22–7

    Article  PubMed  Google Scholar 

  11. Jorns TP, Zakrzewska JM. Evidence-based approach to the medical management of trigeminal neuralgia. Br J Neurosurg 2007; 21(3): 253–61

    Article  PubMed  CAS  Google Scholar 

  12. Maryanoff BE. Pharmaceutical “gold” from neurostabilizing agents: topiramate and successor molecules. J Med Chem 2009; 52: 3431–40

    Article  PubMed  CAS  Google Scholar 

  13. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo controlled study. J Clin Psychiatry 2007; 68: 201–6

    Article  PubMed  CAS  Google Scholar 

  14. van Passel L, Arif H, Hirsch L, et al. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother 2006; 6: 19–31

    Article  PubMed  Google Scholar 

  15. Johnson BA, Capece JA, Wiegand F, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641–51

    Article  PubMed  CAS  Google Scholar 

  16. Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55: 1587–8

    Article  PubMed  CAS  Google Scholar 

  17. Weintraub D, Buchsbaum R, Spencer HT, et al. Cognitive side effects from the Columbia anti-epileptic drug database [abstract]. Neurology 2004; 63 Suppl. 5: A311

    Google Scholar 

  18. Domingues RB, Kuster GW, Aquino CC. Treatment of trigeminal neuralgia with low doses of topiramate. Arq Neuropsiquiatr 2007; 65(3B): 792–4

    Article  PubMed  Google Scholar 

  19. Solaro C, Uccelli MM, Brichetto G, et al. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage 2001; 21(5): 367–8

    Article  PubMed  CAS  Google Scholar 

  20. Gilron I, Booher SL, Rowan JS, et al. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001; 24(2): 109–12

    Article  PubMed  CAS  Google Scholar 

  21. Chen JB. Effectiveness of topiramate in the treatment of primary trigeminal neuralgia. J Pract Med 2008; 24(21): 3738–9

    Google Scholar 

  22. Dong BN, Yuan YL, Zhao HH, et al. Observation on effectiveness and safety of topiramate in the treatment of primary trigeminal neuralgia. Chin J Diffic Compl Cas 2008; 7(11): 680–1

    Google Scholar 

  23. Zeng XJ, Chen QT. Clinical observation on effectiveness of topiramate in the treatment of primary trigeminal neuralgia. Guang Dong Med 2009; 30(4): 631–2

    CAS  Google Scholar 

  24. Gong JJ. A randomized controlled trial of 3 drugs in the treatment of primary trigeminal neuralgia. J Trad Chinese Med 2010; 2(12): 74

    Google Scholar 

  25. Li MQ, Huang XY, Zhu CL, et al. Topiramate and carbamazepine in the treatment of primary trigeminal neuralgia: a randomized controlled trial. China Mod Med 2010; 17(2): 52–3

    CAS  Google Scholar 

  26. Xia YJ. Observation on efficacy of topiramate in the treatment of primary trigeminal neuralgia. Prim Med Care Forum 2010; 14(3): 241–2

    Google Scholar 

  27. Spacek A, Hanl G, Groiss O, et al. Acupuncture and gang-lionic local opioid analgesia in trigeminal neuralgia. Wien Med Wochenschr 1998; 148(19): 447–9

    PubMed  CAS  Google Scholar 

  28. Zheng F, Deng F. Therapeutics of pain [M]. Shanghai: Shanghai Science and Technology Press, 1996: 55–8

    Google Scholar 

  29. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. West Sussex: Cochrane Handbook for Systematic Reviews of Interventions, 2011 Mar

  30. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998; 19: 159–66

    Article  PubMed  CAS  Google Scholar 

  31. Zhao RS, Huang J, Yang L, et al. Pharmacokinetics and bioequivalence of topiramate tablets in healthy volunteers. Chin J Clin Pharmacol 2005; 21(6): 441–4

    CAS  Google Scholar 

  32. Chen HI, Lee JY. The measurement of pain in patients with trigeminal neuralgia. Clin Neurosurg 2010; 57: 129–33

    PubMed  Google Scholar 

  33. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9(2): 105–21

    Article  PubMed  Google Scholar 

  34. Lee JY, Chen HI, Urban C, et al. Development of and psychometric testing for the Brief Pain Inventory-Facial in patients with facial pain syndromes. J Neurosurg 2010; 113(3): 516–23

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Ding Lei for providing valuable advice for this article. We also thank all staff members of the Cochrane Collaboration for providing Cochrane methodology and the Cochrane RevMan 5.1 programme that was used in this article. No sources of funding were used to prepare this study. All authors agree with the opinions and conclusions expressed in this manuscript and have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Dujiangyan People’s Hospital, Dujiangyan Medical Center, Baolian street no.1, Dujiangyan, 611830, China

    Qiang ping Wang & Min Bai

Authors
  1. Qiang ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiang ping Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Q.p., Bai, M. Topiramate versus Carbamazepine for the Treatment of Classical Trigeminal Neuralgia. CNS Drugs 25, 847–857 (2011). https://doi.org/10.2165/11595590-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11595590-000000000-00000

Keywords

Search

Navigation